APA

Kushlinskii N. E., Gershtein E. S., Solov'ev Y. N., Timofeev Y. S., Babkina I. V., Dolinkin A. O., Zuev A. A. & Kostyleva O. I. (20180514). Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. : Bulletin of experimental biology and medicine.

Chicago

Kushlinskii N E, Gershtein E S, Solov'ev Yu N, Timofeev Yu S, Babkina I V, Dolinkin A O, Zuev A A and Kostyleva O I. 20180514. Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. : Bulletin of experimental biology and medicine.

Harvard

Kushlinskii N. E., Gershtein E. S., Solov'ev Y. N., Timofeev Y. S., Babkina I. V., Dolinkin A. O., Zuev A. A. and Kostyleva O. I. (20180514). Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. : Bulletin of experimental biology and medicine.

MLA

Kushlinskii N E, Gershtein E S, Solov'ev Yu N, Timofeev Yu S, Babkina I V, Dolinkin A O, Zuev A A and Kostyleva O I. Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. : Bulletin of experimental biology and medicine. 20180514.